Pimicotinib (ABSK021) is an oral, small-molecule inhibitor of colony-stimulating factor-1 receptor (CSF-1R) that is under clinical investigation in patients with tenosynovial giant cell tumor (TGCT). Pimicotinib is being developed by Abbisko Therapeutics Co. Ltd., Shanghai, China. Merck KGaA, Darmstadt, Germany holds the rights to commercialize pimicotinib worldwide.

Learn more about all pimicotinib (ABSK021) clinical trials at clinicaltrials.gov

Precemtabart tocentecan (M9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) ADC with a β-glucuronide linker-payload combination in clinical development that is designed to selectively deliver exatecan, a TOP1-inhibitor (topoisomerase-1), to CEACAM5-overexpressing tumor cells. It is under clinical investigation in patients with advanced colorectal cancer (CRC) and other solid tumors.

Phase 1 study in patients with advanced CRC: click here to see the PROCEADE-CRC-01 study design

Phase 1b/2 study in patients with advanced solid tumors (gastric cancer/gastroesophageal junction cancer, non-small cell lung cancer, and pancreatic ductal adenocarcinoma): click here to see the PROCEADE-PanTumor study design

Learn more about all Precem-TcT clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting for Precem-TcT clinical trials

M3554 is an anti-GD2 (ganglioside D 2) ADC with a β-glucuronide-exatecan linker-payload combination that is designed to selectively deliver exatecan, aTOP1-inhibitor, to tumors with GD2 expression. It is under clinical investigation in patients with soft tissue sarcoma and glioblastoma.

Phase 1 study in patients with soft tissue sarcoma and glioblastoma: click here to see the study design

Learn more about all M3554 clinical trials at clinicaltrials.gov

Click here to find participating sites currently recruiting for M3554 clinical trials

M7437 is an anti-Ly6E (lymphocyte antigen 6E) ADC with β-glucuronide-exatecan linker-payload combination that is designed to selectively deliver exatecan, a TOP-1 inhibitor, to Ly6E overexpressing tumor cells. It is under clinical investigation in patients with advanced solid tumors.

Phase 1 study in patients with advanced solid tumors: click here to see the study design

Learn more about all M7437 clinical trials at clinicaltrials.gov

Click here to find participating sites currently recruiting for M7437 clinical trials

M0324 is a MUC-1 (mucin-1)-conditional CD40 agonist (bispecific antibody) that is engineered to selectively activate immune cells in the presence of MUC-1 expressing tumor cells. It is under clinical investigation in patients with advanced solid tumors, including metastatic pancreatic ductal adenocarcinoma and tumor types known to overexpress MUC-1.

Phase 1 study in patients with advanced solid tumors: click here to see the TITER study design

Learn more about all M0324 clinical trials at clinicaltrials.gov

Click here to find participating sites currently recruiting for M0324 clinical trials